Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lawrence A Leiter1, Michael A Nauck2

  • 1Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, 61 Queen St. East #6121, Toronto, Ontario, Canada, M5C 2T2.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|July 21, 2017
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively lower blood sugar in type 2 diabetes, comparable to insulin. These agents offer weight loss benefits and cardiovascular protection with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Efficacy of phytosterols for reduction of cardiometabolic risk factors: An umbrella review of systematic reviews and meta-analyses and updated dose-response meta-analyses of randomized trials.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

Diabetes care·2026
Same author

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Circulation·2026
Same author

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Circulation·2026
Same author

Effect of Different Types of Whole Dietary Pulses on Established Therapeutic Lipid Targets for Cardiovascular Risk Reduction: An Updated Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.

Journal of the American Heart Association·2026

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management requires effective glucose-lowering strategies.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a significant therapeutic class for T2DM.
  • GLP-1RAs offer benefits beyond glycemic control, including weight management and cardiovascular risk reduction.

Purpose of the Study:

  • To review phase 3 clinical trial data on the efficacy and safety of available GLP-1RAs.
  • To compare the glucose-lowering effects, hypoglycemic risk, and weight impact of GLP-1RAs.
  • To discuss how variations in GLP-1RA structure and pharmacokinetics influence clinical application.

Main Methods:

  • Systematic review of phase 3 glycaemic control trials for GLP-1RAs.

Related Experiment Videos

  • Analysis of reported changes in HbA1c, body weight, and hypoglycemic events.
  • Evaluation of cardiovascular outcome trial data and adverse event profiles.

    • Main Results:

    • GLP-1RAs demonstrate robust glucose-lowering effects, comparable to insulin, with HbA1c reductions ranging from -1.9% to -0.7%.
    • These agents are associated with a low risk of hypoglycemia and significant weight loss (ranging from -4.0 to -0.4 kg).
    • Cardiovascular benefits are evident with some agents, and gastrointestinal adverse events are typically mild to moderate.

    Conclusions:

    • GLP-1RAs are highly effective in managing type 2 diabetes, offering glycemic control, weight reduction, and potential cardiovascular benefits.
    • Differences in drug structure and pharmacokinetics impact administration frequency, efficacy, and safety profiles.
    • Individual patient needs should guide the selection of appropriate GLP-1RAs for optimal therapeutic outcomes.